Skip to main content

Advertisement

Table 1 Biologicals targeting Th2 inflammation and their main effects

From: Type 2 immunity in asthma

Drug Exacerbations Lung Function QoL
Mepolizumab (ANTI IL-5) Reduction [92, 94,95,96] Increase [92, 96]; no variation in FEV1 [94, 96] Increase [94, 97, 98], no variation in QoL [96]
Reslizumab (ANTI IL-5) Reduction [100, 101] Increase of FEV1 [102] Increase of QoL [100]
Benralizumab (ANTI IL-5Ra) Reduction [103, 106,107,108,109] Increase of FEV1 [107,108,109]; no variation [106] Increase of QoL [107,108,109]; no variation [106]
Pitrakinra (ANTI IL-4) Reduction in homozygous for the rs8832 common G allele, rs1029489, and the intronic SNPs rs3024585, rs3024622 and rs4787956 [111] Reduction [111] n.a.
Dupilumab (ANTI IL-4rα) Reduction [112, 113] Increase of FEV1 [112, 113] Increase of QoL [14, 112]
Lebrikizumab (ANTI IL-13) Reduction in high periostin group [115] Increase of FEV1 in high periostin group [115, 116], response in high periostin, IgE and eosinophils group, [117], no variation [118] No variation [115]
Tralokinumab (ANTI IL-13) Reduction in high-periostin and high-DPP-4 groups [119] Increase in high-periostin and high-DPP-4 groups [119] Increase of QoL [120]
Tezepelumab (ANTI TSLP) Reduction [122] Increase [122] Increase at medium and high dosage [122]